The treatment of polycythaemia vera: an update in the JAK2 era.

Abstract excerpt

The clinical course of polycythaemia vera is marked by a high incidence of thrombotic complications, which represent the main cause of morbidity and mortality. Major predictors of vascular events are increasing age and previous thrombosis. Myelosuppressive drugs can reduce the rate of thrombosis, but there is concern that their use raises the risk of transformation into acute leukaemia. To tackle this dilemma, a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to JAK2 gene
• Share to Janus Kinase 2
• Share to Mutation